Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Equity Average (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Equity Average for 10 consecutive years, with $159.8 million as the latest value for Q4 2025.

  • Quarterly Equity Average changed N/A to $159.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $40.7 million for FY2023, 34.68% down from the prior year.
  • Equity Average for Q4 2025 was $159.8 million at Crescent Biopharma, up from $127.9 million in the prior quarter.
  • The five-year high for Equity Average was $159.8 million in Q4 2025, with the low at -$15.7 million in Q1 2025.
  • Average Equity Average over 5 years is $66.9 million, with a median of $54.5 million recorded in 2025.
  • Peak annual rise in Equity Average hit 1264.01% in 2025, while the deepest fall reached 146.73% in 2025.
  • Over 5 years, Equity Average stood at $89.1 million in 2021, then crashed by 48.9% to $45.5 million in 2022, then decreased by 6.68% to $42.5 million in 2023, then tumbled by 77.92% to $9.4 million in 2024, then surged by 1603.86% to $159.8 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $159.8 million, $127.9 million, and $54.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.